[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-175055-105":53,"doc-detail-175055-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","target-product-profile-drug-name-strategic-development-process-tool","Target Product Profile - Drug Name - Strategic Development Process Tool","","A structured template for drafting a Target Product Profile for a drug, adapted from FDA guidance and organized to capture essential labeling elements and development considerations. It lays out section-by-section content expectations covering indications and usage, dosing and administration, contraindications, warnings, adverse reactions, drug interactions, and use in specific populations. It further specifies content needs for controlled substance scheduling, overdose description, clinical pharmacology, nonclinical toxicology, clinical studies, storage/handling, and patient counseling information.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/target-product-profile-drug-name-strategic-development-process-tool/175055/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/target-product-profile-drug-name-strategic-development-process-tool/175055.png","ImageObject",442,249,{"name":88,"@type":89},"Melati","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-10-19","2026-09-02",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",9,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What core sections must be included in a Target Product Profile template for drug labeling?","Question",{"text":109,"@type":110},"The template specifies sections such as indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, and drug interactions, along with use in specific populations.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What specific information is required under Use in Specific Populations?",{"text":114,"@type":110},"It calls for subsections including pregnancy, labor and delivery, nursing mothers, pediatric use, geriatric use, and additional specified populations such as renal or hepatic impairment.",{"name":116,"@type":107,"acceptedAnswer":117},"What does the template require for Clinical Pharmacology and Nonclinical Toxicology?",{"text":118,"@type":110},"Clinical pharmacology should cover mechanism of action, pharmacodynamics, and pharmacokinetics with exposure-response and time-course details, while nonclinical toxicology should include carcinogenesis, mutagenesis, fertility impairment, and significant animal toxicology/pharmacology results when applicable.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},175055,1790668444,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":101,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":76},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Target Product Profile: Drug Name \u000b(May be modified for use with devices)\nAdapted from FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool, which can be found at \u0013 HYPERLINK \"https://web.archive.org/web/20170522153344/https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080593.pdf\" \\h \u0014https://web.archive.org/web/20170522153344/https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080593.pdf\u0015\nIndications and Usage\nComments:\nDosage and Administration\nComments:\nDosage Forms and Strengths\nComments:\nContraindications\nComments:\nWarnings and Precautions\nComments:\nAdverse Reactions\nComments:\nDrug Interactions\nComments:\nUse in Specific Populations\nComments:\nPregnancy (This subsection can be omitted if the drug is not absorbed systemically):\nTeratogenic effects: Pregnancy Categories: A, B, C, D, X\nNon-teratogenic effects: Other effects on reproduction, the fetus, or newborn.\nLabor and Delivery: Use during labor or delivery, effects on mother, fetus, duration of labor, delivery, and effects on later growth of newborn.\nNursing Mothers: If the drug is absorbed systemically, information about excretion of drug in human milk and effects on the nursing infant. Describe pertinent adverse events in animal offspring or tumorigenicity potential if it is detected or suspected.\nPediatric Use: Statements relevant to the use of the drug product in the pediatric population (birth to 16 years of age). Cite any limitations, need for monitoring, specific hazards, differences in response, or other information pertinent to the pediatric population.\nGeriatric Use: Statements relevant to the use of the drug product in the geriatric population (age 65 and older). Cite any limitations, need for monitoring, specific hazards, differences in response, or other information pertinent to the referenced population.\nAdditional Subsections: Use of drug in other specified populations (e.g., those with renal or hepatic impairment).\nDrug Abuse and Dependence\nComments:\nControlled Substance: Anticipated DEA schedule.\nAbuse: Identify types of abuse and adverse reactions pertinent to them. Identify particularly susceptible patient populations.\nDependence: Discuss potential for dependence and describe the characteristic effects resulting from psychological or physical dependence.\nOver dosage\nComments:\nDescription\nComments:\nClinical Pharmacology\nComments:\n12.1 Mechanism of Action: Summarize established mechanisms of action in humans at various levels (e.g., receptor membrane, tissue, organ, whole body).  Do not include theorized mechanisms of action.\n12.2 Pharmacodynamics:  Include a description of any biochemical or physiologic pharmacologic effects of the drug or active metabolites related to the drug’s clinical effect or those related to adverse effects or toxicity.  Include data on exposure-response relationship and time course of pharmacodynamic response.\n12.3 Pharmacokinetics:  Describe clinically significant pharmacokinetics of a drug or active metabolites (i.e., pertinent absorption, distribution, metabolism, excretion parameters). Include results of pharmacokinetic studies that establish the absence of an effect, including pertinent human studies and in vitro data.\nNonclinical Toxicology\nComments:\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility:\nResults of long-term carcinogenicity studies — species identified\nMutagenesis results\nReproduction study results\n13.2 Animal Toxicology and/or Pharmacology:  Ordinarily, significant animal data necessary for safe and effective use of the drug in humans should be included in other sections of the labeling, as appropriate. If the pertinent animal data cannot be appropriately incorporated into other sections of the labeling, this subsection can be used.\nClinical Studies\nComments:\nReferences — Can include when labeling must summarize or otherwise rely on recommendation by authoritative scientific b","cbCaiegrsFyk6cc3","https://ap.wps.com/l/cbCaiegrsFyk6cc3","docx",44643,"English","# Indications and Usage\n# Dosage and Administration\n# Dosage Forms and Strengths\n# Contraindications\n# Warnings and Precautions\n# Adverse Reactions\n# Drug Interactions\n# Use in Specific Populations\n## Pregnancy\n## Labor and Delivery\n## Nursing Mothers\n## Pediatric Use\n## Geriatric Use\n## Additional Subsections\n# Drug Abuse and Dependence\n# Overdosage\n# Description\n# Clinical Pharmacology\n## Mechanism of Action\n## Pharmacodynamics\n## Pharmacokinetics\n# Nonclinical Toxicology\n## Carcinogenesis, Mutagenesis, Impairment of Fertility\n## Animal Toxicology and/or Pharmacology\n# Clinical Studies\n# References\n# How Supplied/Storage and Handling\n# Patient Counseling Information","[{\"question\":\"What core sections must be included in a Target Product Profile template for drug labeling?\",\"answer\":\"The template specifies sections such as indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, and drug interactions, along with use in specific populations.\"},{\"question\":\"What specific information is required under Use in Specific Populations?\",\"answer\":\"It calls for subsections including pregnancy, labor and delivery, nursing mothers, pediatric use, geriatric use, and additional specified populations such as renal or hepatic impairment.\"},{\"question\":\"What does the template require for Clinical Pharmacology and Nonclinical Toxicology?\",\"answer\":\"Clinical pharmacology should cover mechanism of action, pharmacodynamics, and pharmacokinetics with exposure-response and time-course details, while nonclinical toxicology should include carcinogenesis, mutagenesis, fertility impairment, and significant animal toxicology/pharmacology results when applicable.\"}]","Target Product Profile - Drug Name - Strategic Development Process Tool | DOCX",1788318040]